# Enliven Therapeutics Inc. (ELVN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $59.32, market value $4.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Enliven Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.9×**. The shares trade at 4.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -1.5%** (5-yr avg -59.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -22.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): 3.2%**. Earnings per share rose 3.2%.

## Financial health
- **Current ratio: 28.66** (quick 28.66). Current assets cover the next year's liabilities 28.66 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Enliven Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Enliven Therapeutics Inc.; the consensus is strong_buy, with an average price target of $73.90 (+25% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 196.5%** (YTD 285.2%, 3-mo 70.9%). The shares are up 196.5% over twelve months including dividends.
- **From 52-week high: -4.8%** (301.2% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.05** (volatility 80%). Beta of 1.05 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ELVN · Page: https://foliofundamentals.com/stocks/elvn

Not investment advice.